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INTRODUCTION
Insulin resistance (IR) is an important risk factor for the
development of atherosclerosis and diabetes and also associ-
ated with obesity and the metabolic syndrome (MetS). Altho-
ugh the link between IR and obesity is not completely under-
stood, recent findings suggest that a variety of fat-derived
factors regulate IR (1). Among them, resistin has been sug-
gested to decrease insulin sensitivity in vitro and in vivo in
rodent animal models (2).
Resistin was cloned in 2001; it is a thiazolidinedione (TZD)-
regulated cytokine expressed in adipose tissue (2). In animal
studies, resistin has been shown to influence hepatic glucose
and lipid metabolism (3, 4), and appears to be a major deter-
minant of hepatic IR induced by a high-fat diet (5). Howev-
er, the data on resistin in humans is conflicting. Some reports
have shown that resistin levels are elevated in individuals with
obesity and diabetes (6-8), whereas other investigators have
not confirmed these findings (9-11). These conflicting find-
ings reflect variations in the study design and experimental
conditions, but more importantly they may reflect the lack
of adjustment for potential confounding factors such as gen-
der, ethnicity, degree of obesity, and differences in fat distri-
bution. Moreover, the role of the body fat mass and distribu-
tion in determining the plasma levels of resistin has not yet
been studied in humans. 
The aim of this study was to determine the plasma levels
of resistin in healthy subjects and subjects with MetS. In addi-
tion, the correlation of resistin levels with clinical, laborato-
ry, including the index of IR and determinants of MetS, and
anthropometric parameters were evaluated.
MATERIALS AND METHODS 
One hundred and twenty Korean men and 180 women,
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The aim of the present study was to investigate the relationship of plasma resistin
levels with determinants of the metabolic syndrome (MetS) and anthropometric param-
eters in healthy Korean subjects. Plasma resistin levels were determined in 276 sub-
jects. In subjects with MetS, the plasma resistin levels were not significantly increased
compared to those without MetS (8.3±4.3 ng/mL vs. 8.5±3.6 ng/mL, respectively,
P=0.84). In addition, the plasma resistin levels were not correlated with the body
mass index, the waist circumference, homeostasis model assessment-insulin resis-
tance (HOMA-IR), fasting plasma glucose or insulin levels. However, the plasma
resistin levels were positively correlated with the abdominal subcutaneous fat (r=
0.18, P<0.01) in all subjects and correlated with TNF α(r=-0.16, P<0.05) and hsCRP
(r=0.15, P<0.05) in subjects without MetS but not with MetS. With multiple linear
regression analysis, these linear associations remained to be significant. The results
of this study show that plasma resistin levels in humans were not associated with
markers of insulin resistance, obesity or other determinants of the MetS.
Key Words : Resistin; Metabolic Syndrome; C-reactive Proteinwho did not take any medication at the time of the study,
and who have no known major illness, were recruited to par-
ticipate in this study from 2005 through 2006. The institu-
tional review board at the health promotion center at Ilsan-
Paik Hospital in Korea approved the study protocol accord-
ing to the Declaration of Helsinki. All subjects provided writ-
ten informed consent to participate in the study. 
Subjects completed a self-administered questionnaire that
included demographic characteristics, general health status,
smoking history, and current medications. Anthropometric
and body composition measurements including heights, waist
and hip-circumference were performed in all study partici-
pants before breakfast, with the subject wearing light cloth-
ing and without shoes. Their body mass index (BMI, kg/m2)
was calculated as an index of their overall adiposity. The waist
circumference was measured midway between the inferior
margin of the last rib and the crest of the ileum in the hori-
zontal plane. Hip circumference was measured around the
pelvis at the point of maximal protrusion of the buttocks.
The circumference was measured to the nearest 0.1 cm. Blood
pressure (BP) was measured from the right arm subsequent
to the participant sitting at rest for a period of 20 min. The
mean of two consecutive blood pressure recordings was used
for statistical analysis. The total body fat and muscle were
then measured by bioimpedance analysis (Inbody 3.0, Bio-
space, Seoul, Korea). One observer performed all of the anthro-
pometric and blood pressure measurements. 
The total cross-sectional abdominal fat and abdominal vis-
ceral tissue (VAT) areas were measured by computed tomog-
raphy (CT) scans (Somatom Plus 4, Siemens, Forchheim,
Germany) using an established protocol (12). A cross-sec-
tional scan, with 10-mm thickness centered at the L4-L5 ver-
tebral disc space, was obtained with the subject in the supine
position using a radiograph of the skeleton as a reference; this
was used to establish the position of the scans to the nearest
millimeter. The abdominal subcutaneous tissue (SAT) area
was calculated by subtracting the VAT area from the total
area of adipose tissue. In addition, the body composition, in-
cluding lean body mass and total body fat, was determined
by a dual energy absorptiometry (DXA; QDR 4500, Holog-
ic, Bedford, MA, U.S.A.) performed with a whole-body scan-
ner. The trunk fat was determined as the amount of fat mea-
sured by the DXA from below the neck to the pelvis, exclud-
ing the limbs. 
Blood samples were collected from all subjects after an over-
night fast (10 hr) between 0830 and 1030 hr, and the sera
were stored at -70℃ until used. Fasting plasma glucose and
lipids were measured enzymatically using an autoanalyzer
(Hitachi 747, Hitachi Ltd., Tokyo, Japan). The plasma insulin
levels were measured by radioimmunoassay (Hitachi E170,
Hitachi Ltd.). The resistin was measured as previously des-
cribed (7) and means of duplicated values were used in anal-
ysis. The IR index calculated from the fasting plasma insulin
and the plasma glucose levels was estimated by the homeosta-
sis model assessment (HOMA) where (13): HOMA=fasting
plasma insulin (lU/mL)×fasting plasma glucose (mM/L)/
22.5. The presence of the MetS was determined according
to the 2005 revised National Cholesterol Education Program
(NCEP) Adult Treatment Panel III criteria (14). We defined
central obesity as a waist circumference ≥90 cm for men or
≥80 cm for women as recommended by the revised NCEP
criteria.
Statistical analysis
SPSS 12.0 software (SPSS Inc., Chicago, IL, U.S.A.) was
used for statistical analysis. A P less than 0.05 were consid-
ered statistically significant. Several variables were logarith-
mically transformed to obtain a normal distribution. We used
the independent-t tests to analyze differences in the body com-
position and biochemical parameters between gender and
between subjects without the MetS and those with the MetS.
We calculated partial correlation analysis and then performed
multiple linear regression analyses. Analyses were controlled
for potential confounders including age and gender. We used
a one-way ANOVA with post hoc analysis to assess for differ-
ences along the quartile hsCRP levels and the tertile of abdom-
inal SAT.
RESULTS
After exclusion of six subjects (3 men and 3 women), because
of incidentally detected diabetes, the analysis was restricted
to 276 subjects (aged from 19 to 70 yr, mean 40±11 yr,
men=108 and women=168) for whom resistin data was avail-
able. BMI ranged from 17.6 to 33.2 kg/m2, with a mean value
of 24.3±3.0 kg/m2. Table 1 summarizes the demographic,
anthropometric and metabolic parameters of subjects enrolled
in this study. The mean BMI was 25.3±2.6 kg/m2 in men
and 23.7±3.0 kg/m2 in women. The finding of obesity was
higher in men (54.6%: n=59, compared to women, 28.6%;
n=48, P<0.001). The waist circumference, waist-hip ratio
(WHR), systolic and diastolic blood pressure, fasting plas-
ma glucose, uric acid, total cholesterol, and triglyceride were
significantly higher in men compared to women. The HDL-
cholesterol was lower in men compared to women. In addi-
tion, all anthropometric parameters were significantly high-
er in men compared to women, except for the total abdomi-
nal fat measured by CT and the fat mass in the trunk area
measured by DXA. The plasma levels of TNF α , and high-
sensitive C-reactive protein (hsCRP) were higher in men, but
resistin was higher in women. Log transformed IL-6 level was
significantly higher in women compared to men (-0.20±1.4
vs. 0.41±0.83, P<0.01). There were no significant differ-
ences between men and women in fasting glucose, insulin
and HOMA-IR.
The clinical, laboratory and anthropometric parameters
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222) and those with MetS (19.6%, n=54) (Table 2). As expect-
ed, all values of metabolic and anthropometric parameters
were significantly different between the two groups. How-
ever, the plasma levels of resistin were not significantly dif-
ferent in comparisons between these two groups (8.3±4.3
vs. 8.5±3.6 ng/mL, respectively, P=0.278). The plasma lev-
els of retinol binding protein 4 and hsCRP were significant-
ly increased in subjects with MetS compared to those with-
out MetS (52.4±20.1 vs. 64.3±26.2 μ g/mL, 0.8±2.0 vs.
1.4±1.3 mg/L, respectively, P<0.01). The plasma levels of
TNF αand log transformed IL-6 were increased in subjects
with MetS but the differences did not reach statistical sig-
nificance. In addition, adiponectin was increased in subjects
without MetS but not in those with MetS (9.1±7.0 μ g/mL vs.
5.2±3.5, respectively, P<0.001).
In order to evaluate potential relationships between plas-
ma levels of resistin and clinical, laboratory and anthropomet-
ric parameters, we performed a correlation analysis (Table 3).
The plasma resistin levels were significantly correlated with
the age of subjects (Pearson’s correlation coefficient, r=0.15,
P=0.019) and increased in women. Thus, the correlation of
resistin levels with other metabolic and anthropometric param-
eters was investigated with a partial correlation analysis adjust-
ed for age and gender. We observed that the plasma levels of
resistin were positively correlated with fat mass, measured
by in-body impedance (data not shown), fat CT or DXA,
especially with the fat mass in the extremities (r=0.13, P<
0.05) and the abdominal SCT (r=0.19, P<0.01). In addition,
resistin was significantly correlated with the hsCRP (r=0.15,
P<0.05). However, resistin was negatively correlated with
the plasma levels of TNF α(r=-0.14, P<0.05). Furthermore,
the plasma levels of resistin did not show any significant cor-
relation with the BMI (r=0.09, P=0.152), waist circumfer-
ence, waist-to-hip ratio, systolic and diastolic BP, plasma glu-
cose, total cholesterol, triglycerides, and HDL-C (Table 3).
Moreover, no correlation of plasma levels of resistin was noted
to be associated with the levels of fasting plasma insulin and
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Data are means±SD. *P<0.05, 
� P<0.01. 
MetS, metabolic syndrome; BMI, body mass index; WHR, waist-hip ratio;
BP, blood pressure; HOMA-IR, homeostasis model assessment-insulin
resistance; HDL, high density lipoprotein; VAT, visceral adipose tissue;
SCT, subcutaneous adipose tissue; hsCRP, high-sensitive c-reactive
protein.
Parameters
Men (n=108,
39.1%)
Women, (n=168,
60.9%)
Age (yr) 40±11 40±10
Weight (kg) 74.1±9.6 59.4±7.5
�
BMI (kg/m
2) 25.3±2.6 23.7±3.0
�
Obesity (n) 59 (54.6%) 48 (28.6%)
�
Waist circumference (cm) 90.3±7.4 80.4±7.4
�
Hip circumference (cm) 101.8±4.8 97.8±5.6
�
WHR 0.89±0.05 0.82±0.06
�
Systolic BP (mmHg) 121.9±15.2 109.7±12.7
�
Diastolic BP (mmHg) 75.8±9.6 67.1±8.1
�
Fasting plasma insulin (pM/L) 40.9±27.6 38.9±29.0
Fasting plasma glucose (mM/L) 5.1±0.5 4.9±0.5
�
HOMA-IR 1.28±0.88 1.18±0.94
Uric Acid (μ M/L) 393.7±74.3 275.5±67.0
�
Total cholesterol (mM/L) 4.83±0.80 4.55±0.76
�
Triglyceride (mM/L) 2.25±1.51 1.39±0.82
�
HDL cholesterol (mM/L) 1.09±0.29 1.24±0.33
�
Total body fat (kg) 17.1±5.0 19.9±4.6
�
Lean mass (kg) 53.8±5.9 37. 5±4.6
�
Trunk fat (kg) 8.7±3.0 8.9±2.8
Total extremity fat (kg) 7.3±2.3 10.2±2.1
�
Total abdominal fat (cm
2) 263.8±89.3 265.4±87.4
Abdominal VAT (cm
2) 111.7±52.5 72.2±38.0
�
Abdominal SCT (cm
2) 152.1±53.7 193.1±64.5
�
TNF α (pg/mL) 7.96±1.30 7.22±1.29
�
IL-6 (pg/mL) 1.49±1.09 1.84±0.88
�
hsCRP (mg/L) 0.8±1.0 0.8±1.2
Fasting resistin (ng/mL) 7.5±4.2 8.9±4.1
�
Table 1. Clinical, laboratory and anthropometric characteristics
of the study subjects according to gender
Data are means±SD. *P<0.01. 
MetS, metabolic syndrome; BMI, body mass index; WHR, waist-hip ratio;
BP, blood pressure; HDL, high density lipoprotein; VAT, visceral adipose
tissue; SCT, subcutaneous adipose tissue; hsCRP, high-sensitive c-reac-
tive protein.
Those without MetS
(n=222, 80.4%)
Those with MetS,
(n=54, 19.6%)
Age (yr) 39±11 45±11*
Men (n, %) 71, 65.7 37, 34.3*
Weight (kg) 62.9±9.6 74.7±11.5*
BMI (kg/m
2) 23.7±2.8 26.7±2.4*
Waist circumference (cm) 82.2±7.8 92.7±7.3*
Hip circumference (cm) 98.5±5.5 103.0±4.9*
WHR 0.83±0.06 0.90±0.05*
Systolic BP (mmHg) 111.7±13.4 126.3±15.6*
Diastolic BP (mmHg) 68.4±8.5 79.6±9.3*
Fasting plasma insulin (pM/L) 34.8±23.7 60.1±36.2*
Fasting plasma glucose (mM/L) 4.9±0.4 5.2±0.6*
HOMA-IR 1.05±0.74 1.93±1.20*
Uric Acid (μ M/L) 309.6±86.4 370.8±91.8*
Total cholesterol (mM/L) 4.63±0.76 4.78±0.88
Triglyceride (mM/L) 1.37±0.71 3.17±1.71*
HDL cholesterol (mM/L) 1.24±0.31 0.95±0.24*
Total body fat (kg) 18.3±4.9 20.8±4.7*
Lean mass (kg) 42.2±8.5 50.5±10.4*
Trunk fat (kg) 8.4±2.7 10.6±2.6*
Total extremity fat (kg) 9.1±2.6 9.2±2.6
Total abdominal fat (cm
2) 248.7±82.6 330.6±78.7*
Abdominal VAT (cm
2) 76.5±39.6 133.5±53.4*
Abdominal SCT (cm
2) 172.2±63.2 197.1±61.8*
TNF α (pg/mL) 7.45±1.33 7.76±1.34
IL-6 (pg/mL) 1.68±0.98 1.81±0.96
hsCRP (mg/L) 0.7±1.1 1.4±1.3*
Fasting resistin (ng/mL) 8.3±4.3 8.5±3.6
Table 2. Comparison of clinical, laboratory and anthropometric
parameters between subjects without the metabolic syndrome
and those with metabolic syndrome
ParametersHOMA-IR. As well, plasma levels of IL-6, RBP4, adiponec-
tin, and leptin were not significantly correlated with plasma
resistin. After adjustment for obesity by BMI, these relation-
ships remained significant, except for the total abdominal
fat and fat mass in the extremities (Table 3). When a partial
correlation analysis were performed in subjects without MetS,
the plasma levels of resistin were positively correlated with
the plasma hsCRP levels (r=0.16, P<0.05) and negatively
correlated with the TNF α(r=-0.16, P<0.05). These obser-
vations remained significant after adjustment for BMI. In
subjects with MetS, plasma levels of resistin were positively
correlated with the hip circumference, total body fat, trunk
fat, extremity fat, leptin and strongly correlated with abdom-
inal subcutaneous adipose tissue (SCT) (Table 3).
We performed a multiple linear regression analysis includ-
ing the parameters, which were significantly correlated with
the plasma resistin levels in all subjects and in subjects with/
without MetS (Table 4). In this analysis, we included only
abdominal SCT because of the interdependence and multi-
colinearity among the variables associated with measurements
of body fat mass. The results of this analysis showed that age
(β =-0.20, P<0.01), abdominal SCT (β =0.26, P<0.01) and
TNF α(β =-0.16, P<0.01) in all subjects; age (β =-0.19, P<
0.01), abdominal SCT (β =0.20, P<0.05), TNF α(β =-0.16,
P<0.05), and hsCRP (β =0.16, P<0.05) in subjects without
MetS and only abdominal SCT (β =0.57, P<0.01) in subjects
with MetS were independent predictors of plasma resistin
levels. 
Fig. 1 shows that the plasma levels of resistin increased
with hsCRP levels and abdominal SCT in subjects without
MetS, however in the second and third tertile of the abdom-
inal SCT, plasma levels of resistin were not significantly dif-
ferent with increases in hsCRP levels.
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*Logarithmic transformation performed before analysis.
β : Standardized coefficients. 
MetS, metabolic syndrome; hsCRP, high-sensitive c-reactive protein; SCT,
subcutaneous adipose tissue. 
Without
MetS
β P
With MetS
β P
Overall
β P
Age (yr) -0.12 <0.01 -0.19 0.01 -0.16 0.24
Abdominal SCT (cm
2)* 0.26 <0.01 0.20 0.03 0.57 <0.01
TNF α (pg/mL) -0.16 0.01 -0.16 0.02 -0.19 0.15
hsCRP (mg/dL)* 0.12 0.07 0.16 0.03 -0.19 0.16
Table 4. Multiple linear regression analysis between plasma lev-
els of resistin, transformed to log, and age, BMI, hsCRP, TNF α
levels, fat mass in the abdominal subcutaneous tissue in all sub-
jects and according to status of the metabolic syndrome
2.5
2.0
1.5
1.0
0.5
0.0
Fig. 1. Mean plasma levels of logarithmic transformed resistin along
high-sensitive C-reactive protein (hsCRP) tertile and abdominal
subcutaneous fat (SCT) quartile in subjects without the metabolic
syndrome.
*P<0.05 vs. respective first quartile of hsCRP. 
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r
a, after adjustment for age and sex; r
b, after adjustment for age, gender
and body mass index. 
MetS, metabolic syndrome; BP, blood pressure; HOMA-IR, homeosta-
sis model assessment-insulin resistance; HDL, high density lipoprotein;
VAT, visceral adipose tissue; SCT, subcutaneous adipose tissue; hsCRP,
high-sensitive c-reactive protein. 
Without
MetS
r
a r
b
With MetS
r
a r
b
Overall
r
a r
b
Waist circumference 0.09 0.03 0.02 -0.02 0.20 0.18
Hip circumference  0.06 -0.01 -0.03 -0.08 0.34* 0.38*
Systolic BP  0.01 -0.03 -0.05 -0.08 0.05 0.02
Diastolic BP  0.03 -0.01 -0.07 -0.08 0.17 0.15
Fasting plasma insulin
� 0.05 0.01 -0.02 -0.03 0.08 0.03
Fasting plasma glucose  0.02 0.01 0.02 0.02 -0.08 -0.08
HOMA-IR
� 0.06 0.01 -0.01 -0.03 0.06 0.01
Uric acid  0.02 0.00 -0.03 -0.03 0.13 0.10
Total cholesterol 0.05 0.04 0.05 0.05 0.04 0.02
Triglyceride
� 0.13 0.11 0.09 0.08 0.02 0.01
HDL cholesterol (mM/L)
� -0.11 -0.09 -0.08 -0.08 0.05 0.07
Total body fat  0.16* 0.14* 0.07 0.07 0.35* 0.35*
Lean mass  0.11 0.07 0.07 0.06 0.12 0.08
Trunk fat  0.16* 0.14* 0.08 0.08 0.31* 0.30*
Total extremity fat 0.13* 0.10 0.04 0.02 0.34* 0.34*
Total abdominal fat  0.13* 0.10 0.05 0.04 0.24 0.25
Abdominal VAT  0.05 -0.01 0.03 0.00 -0.06 -0.12
Abdominal SCT
� 0.19
� 0.18
� 0.12 0.12 0.40* 0.41*
TNF α -0.14* -0.14* -0.16* -0.16* -0.05 -0.05
IL-6
� 0.05 0.05 0.03 0.03 -0.05 -0.07
hsCRP
� 0.15* 0.12 0.16* 0.15* -0.03 -0.05
Table 3. Correlation coefficients between plasma levels of resistin,
transformed to log, and the variables of clinical, laboratory and
anthropometric parameters in all subjects examined and accord-
ing to presence/absence of the metabolic syndrome
* *
*
*
ParametersDISCUSSION
We present one of the first human studies on the plasma
levels of resistin associated with anthropometric parameters.
The results showed no evidence supporting a role for plasma
resistin in mediating visceral obesity or IR in individuals with
the MetS. However, potential associations between resistin
and markers of systemic inflammations, such as hsCRP were
found even in metabolically stable and healthy individuals.
Circulating resistin levels were found to be elevated in ge-
netic (ob/ob and db/db) and diet induced models of obesity (2).
Thiazolidinedione (TZDs), which lower IR by binding to
peroxisome proliferators activated receptor-γ(PPARγ ) recep-
tors, decreased resistin levels in ob/ob mice and diabetic fatty
rats. Tissue-cultured murine adipocytes treated with TZDs
decreased resistin mRNA expression (2, 15). However, other
studies have not supported a role of resistin in mediating IR
in rodents. TZD treatment increased resistin expression in
both lean and obese rodents, including ob/ob mice and Zucker
diabetic fatty rats (16, 17); and resistin expression was incre-
ased by 66% in db/db mice treated with metformin (18). Addi-
tionally, resistin gene expression in 3T3-L1 adipocytes was
inhibited by insulin and TNF α , which are increased in obe-
sity (19, 20). Consistent with these findings, our results showed
that the plasma resistin levels had a inverse relationship with
plasma TNF α . 
Plasma levels of resistin, produced by adipose tissue, might
be present at high circulating levels in subjects with high fat
content. In human, evidence in accumulating that resistin
expression is high in mononuclear blood cells and other non-
adipocytes of adipose tissue than in adipocytes them selves
(20, 21). Therefore, absolute plasma levels of resistin were
increased with generalized obesity and its relationship with
clinical parameters of visceral obesity was not be linear; this
could explain some of the inconsistent findings in human
studies (20). Although previous reports showed that resistin
mRNA was higher in visceral fat than in subcutaneous fat
(22), our data suggests a possible significant association bet-
ween circulating resistin levels and total fat mass or subcu-
taneous fat in humans.
As shown here, the impact of resistin may be more impor-
tant in the regulation of the inflammatory process even in
the lean subjects (23). After adjustment for abdominal SCT,
gender and age, the partial correlation analyses showed that
the plasma levels of resistin were associated with hsCRP (r=
0.15, P=0.040) in subjects without MetS. These findings
suggest that resistin may play a role in inflammation and
could be a potential marker for systemic subclinical inflam-
mation in obesity (24-27). Shetty et al. (11) described a pos-
itive association between resistin and CRP independent of
BMI and gender. Thus, these observations suggest that infla-
mmatory factors are more dominant determinants of plasma
resistin levels than metabolic factors. Further studies are need-
ed to clarify the role of resistin in obesity.
In summary, these results show that the resistin levels are
not associated with markers of IR and/or central obesity. How-
ever, the resistin levels are associated with the total body fat
mass and with markers of systemic inflammation in lean heal-
thy subjects. However, because of this cross-sectional study
design, we cannot suggest any causal or temporal relation-
ship. Further investigations are needed to improve our under-
standing of resistin in humans. 
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